Beurrier S, Peyromaure M, Belas O, Barry Delongchamps N
Service d'urologie, hôpital Cochin, université Paris Descartes, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France.
Service d'urologie, hôpital Cochin, université Paris Descartes, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France; Inserm U1151, Institut Necker, université Paris Descartes, 75014 Paris, France.
Prog Urol. 2015 Jul;25(9):523-9. doi: 10.1016/j.purol.2015.03.005. Epub 2015 Apr 28.
To report the results of UroLift(®) implants after a 2-year experience in the technique.
The procedure was proposed between February 2012 and April 2014 in patients with symptomatic benign prostatic hyperplasia, as an alternative to standard endoscopic ablation techniques. Evaluation of BPH related symptoms relied on the IPSS and IPSS-QoL self-questionnaires, as well as on maximum uroflow (Qmax). Evaluation of erectile and ejaculatory functions relied on the IIEF5 and MSHQ-EjD self-questionnaires, respectively.
A total of 23 patients were treated during this period. Median age was 66 years [53-78]. Median prostate volume was 38mL [20-80]. Preoperative IPSS and IPSS-QoL were 20 [9-29] and 5 [3-6], respectively. No severe adverse event was observed postoperatively. Median follow-up was 14 [5-31] months. At the end of follow-up, 19 (83%) patients reported sustained symptomatic improvement without any additional treatment. Median IPSS and IPSS-QoL were improved significantly (11 [1-27] and 2 [0-6], P<0.0001), with however no significant improvement in Qmax. Four patients needed additional treatment during the first postoperative year. Among them, 3 had a prostate volume>60mL. No patient reported retrograde ejaculation or worsened erectile function.
UroLift(®) implants allowed symptomatic improvement in more than 80% of the patients after 1-year follow-up. A high prostate volume may potentially be predictive of symptomatic failure.
报告在应用UroLift(®)植入术两年后的经验结果。
在2012年2月至2014年4月期间，将该手术推荐给有症状的良性前列腺增生患者，作为标准内镜消融技术的替代方法。通过国际前列腺症状评分（IPSS）和IPSS生活质量（IPSS-QoL）自评问卷以及最大尿流率（Qmax）来评估与良性前列腺增生相关的症状。分别通过国际勃起功能指数5（IIEF5）和男性性功能和射精功能问卷（MSHQ-EjD）自评问卷来评估勃起和射精功能。
在此期间共治疗了23例患者。中位年龄为66岁[53 - 78岁]。中位前列腺体积为38mL[20 - 80mL]。术前IPSS和IPSS-QoL分别为20[9 - 29]和5[3 - 6]。术后未观察到严重不良事件。中位随访时间为14个月[5 - 31个月]。随访结束时，19例（83%）患者报告症状持续改善且无需任何额外治疗。IPSS和IPSS-QoL中位数显著改善（分别为11[1 - 27]和2[0 - 6]，P<0.0001），但Qmax无显著改善。4例患者在术后第一年需要额外治疗。其中3例前列腺体积>60mL。没有患者报告逆行射精或勃起功能恶化。
UroLift(®)植入术使超过80%的患者在1年随访后症状得到改善。前列腺体积较大可能预示症状改善失败。
5级
